JP2017529838A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529838A5 JP2017529838A5 JP2017512813A JP2017512813A JP2017529838A5 JP 2017529838 A5 JP2017529838 A5 JP 2017529838A5 JP 2017512813 A JP2017512813 A JP 2017512813A JP 2017512813 A JP2017512813 A JP 2017512813A JP 2017529838 A5 JP2017529838 A5 JP 2017529838A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 413
- 230000027455 binding Effects 0.000 claims description 119
- 239000012634 fragment Substances 0.000 claims description 119
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 80
- 239000000427 antigen Substances 0.000 claims description 57
- 102000036639 antigens Human genes 0.000 claims description 57
- 108091007433 antigens Proteins 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 description 44
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 7
- 201000005787 hematologic cancer Diseases 0.000 description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 101100310663 Homo sapiens SP1 gene Proteins 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 102000052088 human IL3RA Human genes 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 208000017815 Dendritic cell tumor Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 101100288142 Mus musculus Klkb1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229960004931 histamine dihydrochloride Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046682P | 2014-09-05 | 2014-09-05 | |
| US62/046,682 | 2014-09-05 | ||
| PCT/US2015/048316 WO2016036937A1 (en) | 2014-09-05 | 2015-09-03 | Cd123 binding agents and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199977A Division JP2021050216A (ja) | 2014-09-05 | 2020-12-02 | Ｃｄ１２３結合剤及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529838A JP2017529838A (ja) | 2017-10-12 |
| JP2017529838A5 true JP2017529838A5 (enExample) | 2018-10-11 |
| JP6805130B2 JP6805130B2 (ja) | 2020-12-23 |
Family
ID=54150667
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512813A Active JP6805130B2 (ja) | 2014-09-05 | 2015-09-03 | Ｃｄ１２３結合剤及びその使用 |
| JP2020199977A Ceased JP2021050216A (ja) | 2014-09-05 | 2020-12-02 | Ｃｄ１２３結合剤及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199977A Ceased JP2021050216A (ja) | 2014-09-05 | 2020-12-02 | Ｃｄ１２３結合剤及びその使用 |
Country Status (39)
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4477668A3 (en) * | 2010-04-20 | 2025-03-19 | Genmab A/S | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| TN2017000275A1 (en) | 2015-01-23 | 2018-10-19 | Sanofi Sa | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| US10100118B2 (en) | 2015-04-08 | 2018-10-16 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD123 |
| WO2016187594A1 (en) | 2015-05-21 | 2016-11-24 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| SI3313884T1 (sl) | 2015-06-29 | 2021-04-30 | Immunogen, Inc. | Protitelesa proti CD123 ter njihovi konjugati in derivati |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| MA44082A (fr) | 2015-12-14 | 2018-10-24 | Macrogenics Inc | Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CA3024683A1 (en) * | 2016-05-20 | 2017-11-23 | Harpoon Therapeutics, Inc. | Single chain variable fragment cd3 binding proteins |
| JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス，インク． | 単一ドメイン血清アルブミン結合タンパク質 |
| KR102187751B1 (ko) | 2016-06-06 | 2020-12-08 | 에프. 호프만-라 로슈 아게 | 눈 잔류가 증가된 안과학용 융합 단백질 |
| MA45192A (fr) | 2016-06-07 | 2019-04-10 | Macrogenics Inc | Traitement d'association |
| TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| TWI781108B (zh) * | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| CN107840889A (zh) * | 2016-09-19 | 2018-03-27 | 上海吉倍生物技术有限公司 | 高亲和力的抗cd123抗体及其应用 |
| PH12019500609B1 (en) * | 2016-09-21 | 2024-02-21 | Aptevo Res & Development Llc | Cd123 binding proteins and related compositions and methods |
| CA3044729A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Psma targeting trispecific proteins and methods of use |
| KR20210087108A (ko) | 2016-11-23 | 2021-07-09 | 하푼 테라퓨틱스, 인크. | 전립선 특이 막 항원 결합 단백질 |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| AU2018215673B2 (en) * | 2017-02-06 | 2025-01-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for augmenting antibody mediated receptor signaling |
| MA47612A (fr) | 2017-02-24 | 2020-01-01 | Macrogenics Inc | Molécules de liaison bispécifiques capables de se lier à cd137 et à des antigènes tumoraux, et leurs utilisations |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| US12145974B2 (en) * | 2017-03-14 | 2024-11-19 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising FGF21 and GLP-1, connected through a Fc portion of an immunoglobulin |
| IL300964A (en) | 2017-05-12 | 2023-04-01 | Harpoon Therapeutics Inc | mesothelin binding proteins |
| WO2018209304A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| WO2019034580A1 (en) | 2017-08-14 | 2019-02-21 | Morphosys Ag | HUMANIZED ANTIBODIES FOR CD3 |
| WO2019050521A1 (en) * | 2017-09-07 | 2019-03-14 | Macrogenics, Inc. | DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES |
| PE20201183A1 (es) | 2017-10-13 | 2020-11-03 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| US11613581B2 (en) * | 2017-10-27 | 2023-03-28 | Pfizer, Inc. | Antibodies and antibody-drug conjugates specific for CD123 and uses thereof |
| CA3085432A1 (en) | 2017-12-12 | 2019-06-20 | Macrogenics Inc. | Bispecific cd16-binding molecules and their use in the treatment of disease |
| CN111787949A (zh) | 2018-02-15 | 2020-10-16 | 宏观基因有限公司 | 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途 |
| CN120399075A (zh) * | 2018-03-14 | 2025-08-01 | 诺维莫尼公司 | 抗-CD3ε抗体及其应用方法 |
| KR20210020903A (ko) | 2018-05-14 | 2021-02-24 | 하푼 테라퓨틱스, 인크. | 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티 |
| MY203469A (en) * | 2018-05-16 | 2024-06-28 | Stichting Vumc | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
| JOP20190116A1 (ar) * | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| BR112020023872A2 (pt) | 2018-05-24 | 2021-02-17 | Janssen Biotech, Inc. | agentes de ligação de psma e seus usos |
| US11866499B2 (en) | 2018-05-24 | 2024-01-09 | Janssen Biotech, Inc. | Monospecific and multispecific anti-TMEFF2 antibodies and their uses |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| CA3114038A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| WO2020080853A1 (ko) * | 2018-10-17 | 2020-04-23 | 주식회사 굳티셀 | Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도 |
| TWI874341B (zh) | 2018-12-18 | 2025-03-01 | 美商健生生物科技公司 | 產生異二聚體抗體之方法 |
| MX2021010857A (es) * | 2019-03-11 | 2021-12-15 | Janssen Biotech Inc | Anticuerpos biespecificos anti-v(beta17)/anti-cd123. |
| KR20220002899A (ko) | 2019-04-19 | 2022-01-07 | 얀센 바이오테크 인코포레이티드 | 항-psma/cd3 항체로 전립선암을 치료하는 방법 |
| BR112021022089A2 (pt) * | 2019-05-08 | 2022-02-08 | Janssen Biotech Inc | Materiais e métodos para modulação da imunidade mediada por células t |
| CN114245806A (zh) | 2019-05-14 | 2022-03-25 | 哈普恩治疗公司 | EpCAM结合蛋白及使用方法 |
| CN120775051A (zh) | 2019-05-21 | 2025-10-14 | 诺华股份有限公司 | Cd19结合分子及其用途 |
| CN113912697B (zh) * | 2019-07-24 | 2023-05-30 | 暨南大学 | 靶向cd133的结合蛋白与应用 |
| GB201912681D0 (en) | 2019-09-04 | 2019-10-16 | Eth Zuerich | Bispecific binding agent that binds to cd117/c-kit and cd3 |
| BR112022015656A2 (pt) | 2020-02-21 | 2022-09-27 | Macrogenics Inc | Moléculas de ligação ao cd137, molécula de ligação ao pd-l1, composição farmacêutica, e ácido nucleico |
| AU2021224851A1 (en) | 2020-02-21 | 2022-09-15 | Harpoon Therapeutics, Inc. | FLT3 binding proteins and methods of use |
| JOP20220220A1 (ar) | 2020-03-13 | 2023-01-30 | Janssen Biotech Inc | مواد وطرق لربط لكتين شبيه بالجوبيولين المناعي بحمض سياليك |
| WO2021236841A2 (en) | 2020-05-19 | 2021-11-25 | The Regents Of The University Of California | Conjugate polypeptides and vaccines for inducing immune responses |
| JP2023527164A (ja) * | 2020-05-19 | 2023-06-27 | ヤンセン バイオテツク，インコーポレーテツド | Ｔ細胞リダイレクト治療薬及びｖｌａ－４接着経路阻害剤を含む組成物 |
| WO2022056192A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Methods and compositions for modulating beta chain mediated immunity |
| TW202233673A (zh) * | 2020-10-23 | 2022-09-01 | 美商雅雪生物治療公司 | 含調節免疫細胞功能之ｃｄ８抗原結合分子之融合物 |
| AU2021414400A1 (en) | 2020-12-31 | 2023-08-17 | Innate Pharma | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
| WO2022165171A1 (en) | 2021-01-28 | 2022-08-04 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| EP4340942A1 (en) * | 2021-05-18 | 2024-03-27 | Janssen Biotech, Inc. | Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic |
| GB2638094A (en) | 2021-05-19 | 2025-08-13 | Asher Biotherapeutics Inc | Il-21 Polypeptides And Targeted Constructs |
| CA3228654A1 (en) * | 2021-08-09 | 2023-02-16 | Brian Rabinovich | Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines |
| CN118574646A (zh) * | 2022-01-19 | 2024-08-30 | 上海优替济生生物医药有限公司 | 环状rna及其用途 |
| KR20250004700A (ko) | 2022-04-11 | 2025-01-08 | 리제너론 파마슈티칼스 인코포레이티드 | 보편적 종양 세포 사멸을 위한 조성물 및 방법 |
| JP7747911B2 (ja) | 2022-05-27 | 2025-10-01 | サノフイ | ＮＫｐ４６に結合するナチュラルキラー（ＮＫ）細胞エンゲージャー及びＦＣエンジニアリングを有するＢＣＭＡ変異体 |
| AU2024223918A1 (en) | 2023-02-17 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US6177078B1 (en) | 1995-12-29 | 2001-01-23 | Medvet Science Pty Limited | Monoclonal antibody antagonists to IL-3 |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| EP1015576B1 (en) | 1997-09-16 | 2005-05-04 | Egea Biosciences, LLC | Method for the complete chemical synthesis and assembly of genes and genomes |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20060204493A1 (en) | 2004-09-02 | 2006-09-14 | Genentech, Inc. | Heteromultimeric molecules |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| WO2007059782A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| EP2035456A1 (en) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
| JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| EP2426148B1 (en) * | 2009-04-27 | 2015-08-05 | Kyowa Hakko Kirin Co., Ltd. | Anti-il-3ra antibody for use in treatment of blood tumor |
| AU2010298036B2 (en) * | 2009-09-25 | 2015-05-21 | Xoma Technology Ltd. | Screening methods |
| EP4477668A3 (en) | 2010-04-20 | 2025-03-19 | Genmab A/S | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| NZ604510A (en) * | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
| US9562109B2 (en) | 2010-11-05 | 2017-02-07 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| EP2773671B1 (en) | 2011-11-04 | 2021-09-15 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| HUE059815T2 (hu) * | 2012-05-18 | 2022-12-28 | Aptevo Res & Development Llc | Bispecifikus SCFV immunofuziós (BIF) kötõdés a CD123-hoz és a CD3-hoz |
-
2015
- 2015-09-03 RS RS20200573A patent/RS60305B1/sr unknown
- 2015-09-03 UA UAA201703200A patent/UA120060C2/uk unknown
- 2015-09-03 EA EA201790530A patent/EA037647B1/ru unknown
- 2015-09-03 MY MYPI2017700741A patent/MY186337A/en unknown
- 2015-09-03 JO JOP/2015/0216A patent/JO3568B1/ar active
- 2015-09-03 SG SG11201701599UA patent/SG11201701599UA/en unknown
- 2015-09-03 CA CA2959171A patent/CA2959171C/en active Active
- 2015-09-03 PT PT157669730T patent/PT3189081T/pt unknown
- 2015-09-03 MX MX2017002891A patent/MX384424B/es unknown
- 2015-09-03 SM SM20200253T patent/SMT202000253T1/it unknown
- 2015-09-03 WO PCT/US2015/048316 patent/WO2016036937A1/en not_active Ceased
- 2015-09-03 SI SI201531192T patent/SI3189081T1/sl unknown
- 2015-09-03 EP EP20157898.6A patent/EP3722315A1/en not_active Withdrawn
- 2015-09-03 MA MA053145A patent/MA53145A/fr unknown
- 2015-09-03 JP JP2017512813A patent/JP6805130B2/ja active Active
- 2015-09-03 HU HUE15766973A patent/HUE048791T2/hu unknown
- 2015-09-03 CR CR20170079A patent/CR20170079A/es unknown
- 2015-09-03 LT LTEP15766973.0T patent/LT3189081T/lt unknown
- 2015-09-03 US US14/844,194 patent/US9850310B2/en active Active
- 2015-09-03 CN CN201580060369.4A patent/CN107074956B/zh active Active
- 2015-09-03 ME MEP-2020-93A patent/ME03724B/me unknown
- 2015-09-03 AU AU2015311931A patent/AU2015311931B2/en not_active Ceased
- 2015-09-03 PE PE2017000397A patent/PE20171556A1/es unknown
- 2015-09-03 TW TW104129109A patent/TWI693233B/zh not_active IP Right Cessation
- 2015-09-03 ES ES15766973T patent/ES2791249T3/es active Active
- 2015-09-03 PL PL15766973T patent/PL3189081T3/pl unknown
- 2015-09-03 KR KR1020177008815A patent/KR102540192B1/ko active Active
- 2015-09-03 EP EP15766973.0A patent/EP3189081B1/en active Active
- 2015-09-03 MA MA40609A patent/MA40609B1/fr unknown
- 2015-09-03 HR HRP20200745TT patent/HRP20200745T1/hr unknown
- 2015-09-03 DK DK15766973.0T patent/DK3189081T3/da active
- 2015-09-04 AR ARP150102836A patent/AR101765A1/es unknown
- 2015-09-04 UY UY0001036289A patent/UY36289A/es not_active Application Discontinuation
-
2017
- 2017-02-26 IL IL250770A patent/IL250770B/en active IP Right Grant
- 2017-03-03 NI NI201700025A patent/NI201700025A/es unknown
- 2017-03-03 CL CL2017000515A patent/CL2017000515A1/es unknown
- 2017-03-06 CO CONC2017/0002196A patent/CO2017002196A2/es unknown
- 2017-03-13 PH PH12017500472A patent/PH12017500472A1/en unknown
- 2017-04-04 ZA ZA2017/02369A patent/ZA201702369B/en unknown
- 2017-04-05 EC ECIEPI201720812A patent/ECSP17020812A/es unknown
-
2020
- 2020-05-18 CY CY20201100453T patent/CY1122858T1/el unknown
- 2020-12-02 JP JP2020199977A patent/JP2021050216A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529838A5 (enExample) | ||
| JP2018534933A5 (enExample) | ||
| JP2021184721A5 (enExample) | ||
| JP2020516240A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2020504723A5 (enExample) | ||
| JP2013527761A5 (enExample) | ||
| JP2019536806A5 (enExample) | ||
| JP2017512765A5 (enExample) | ||
| JP2017526339A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| JP2017534256A5 (enExample) | ||
| RU2016144176A (ru) | Биспецифические антитела к her2 | |
| JP2020509027A5 (enExample) | ||
| JP2015503909A5 (enExample) | ||
| JP2017510559A5 (enExample) | ||
| JP2014511179A5 (enExample) | ||
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| JP2013510868A5 (enExample) | ||
| JP2012521218A5 (enExample) | ||
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 | |
| JP2020522281A5 (enExample) | ||
| JP2020522280A5 (enExample) | ||
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 |